TruSight Oncology 500 ctDNA

Assay targeting multiple somatic variant types from plasma, including microsatellite instability (MSI) and tumor mutational burden (TMB). Read More...
Select Product(s)

TruSight Oncology 500 ctDNA Kit (48 samples)

20039252

Price
 
 
Accessory Products

NovaSeq 6000 S2 Reagent Kit (300 cycles)

20012860

Price
 
 

NovaSeq 6000 S4 Reagent Kit (300 cycles)

20012866

Price
 
 

NovaSeq Xp 4-Lane Kit

20021665

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 1, 1 Year License

20042100

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 2, 1 Year License

20042101

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 3, 1 Year License

20042102

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 4, 1 Year License

20042103

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 5, 1 Year License

20042104

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 6, 1 Year License

20042105

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 7, 1 Year License

20042106

Price
 
 

DRAGEN TruSight Oncology 500 ctDNA Analysis Software, Level 8, 1 Year License

20042107

Price
 
 

Illumina DRAGEN Server v3

20040619

Product Highlights

An NGS-based assay that assesses multiple variant types in 523 cancer-related genes from cell-free DNA (cfDNA). Leveraging the power of the NovaSeq 6000 System for high depth of sequencing, unique molecular identifiers (UMIs), and the ultra-rapid Illumina DRAGEN Server v3, provides high sensitivity and specificity to enable comprehensive genomic profiling from cfDNA.

Enable Comprehensive Genomic Profiling in Plasma

  • Same DNA content as TruSight Oncology 500 for detection of single nucleotide variants (SNVs), indels, CNVs, DNA fusions, TMB, and MSI

Achieve Rapid, Accurate Variant Detection

  • Highly sophisticated variant calling algorithm powered and accelerated by DRAGEN

Achieve Confidence in Results

  • Hybrid-capture chemistry, UMIs and high depth of coverage, and sophisticated error correction improve variant calling and reduce artifacts

Leverage the Power of the NovaSeq 6000 System

  • Enable cfDNA analysis with the required depth of sequencing for low-level variant detection in plasma
Learn more about TruSight Oncology 500 Family

TruSight Oncology 500 Product Family

All three assays in the family are designed to identify key biomarkers in guidelines and clinical trials.

TruSight Oncology 500 Assay

Assess key cancer biomarkers from FFPE tumor tissue with the TruSight Oncology 500 Assay.

TruSight Oncology 500 High-Throughput Assay

Batch up to 192 samples at a time while using the same biomarkers and tissue type as the TruSight Oncology 500 assay.

TruSight Oncology 500 ctDNA Assay

Analyze circulating tumor DNA from plasma with the TruSight Oncology 500 ctDNA assay.

Frequently Purchased Together

Specifications

Project Recommendations

Instrument Recommended Number of Samples Read Length
NovaSeq 6000 System 24 samples per run (S4 flow cell), 800M paired-end reads, 35,000x coverage 2 × 150 bp
NovaSeq 6000 System 8 samples per run (S2 flow cell), 800M paired-end reads, 35,000x coverage 2 × 150 bp

Product Comparison

TruSight Oncology 500 ctDNA TruSight Oncology 500 TruSight Oncology 500 High-Throughput
Assay Time 5 days from sample to variant report 4-5 days from sample to answer 4-5 days from nucleic acid to variant report
Cancer Type Pan-Cancer Pan-Cancer Pan-Cancer
Content Specifications Targeted selection of DNA from 523 genes of interest for a total of 1.94Mb panel size. Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 1,000 clinical trials
• Immuno-oncology Biomarker Coverage: Coverage MSI biomarkers, as well as emerging biomarkers TMB, POLE1 and POLD1
Targeted selection of DNA from 523 genes of interest, and RNA from 55 genes, for a total of 1.94Mb panel size.
• Guideline Coverage: Broad coverage of key guidelines for multiple solid tumor types
• Clinical Trials Coverage: Over 1,000 clinical trials
• Immuno-oncology Biomarker Coverage: Coverage MSI biomarkers, as well as emerging biomarkers TMB, POLE1 and POLD1
Hands-On Time ~10.5 hours ~10.5 hours ~10.5 hours
Input Quantity 30 ng cfDNA (8-10 ml of plasma) 40 ng DNA, 40 ng RNA 40 ng DNA, 40-80 ng RNA (need at least 2 mm3 FFPE tissue)
Method Target Enrichment , Target Enrichment, Targeted DNA Sequencing Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing Target Enrichment , Target Enrichment, Targeted DNA Sequencing , Targeted RNA Sequencing
Nucleic Acid Type DNA DNA, RNA DNA, RNA
Specialized Sample Types Blood, Cell-Free DNA, Circulating Tumor DNA FFPE Tissue FFPE Tissue
Species Category Human Human Human
System Compatibility NovaSeq 6000 NextSeq 2000 , NextSeq 500 , NextSeq 550 , NextSeq 550Dx in Research Mode NovaSeq 6000
Technology Sequencing Sequencing Sequencing
Variant Class Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Somatic Variants Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants Copy Number Variants (CNVs), Gene Fusions, Insertions-Deletions (indels), Single Nucleotide Variants (SNVs), Transcript Variants
Liquid Biopsy Offers Advantages in the Modern Age

Innovations in molecular assays enable comprehensive, precise analysis of cell-free DNA.

Read Application Spotlight
Liquid Biopsy Offers Advantages in the Modern Age

Method-Specific Workflow Example

 

Related Products